首页 | 本学科首页   官方微博 | 高级检索  
     

43例肝细胞肝癌患者行肝动脉化疗栓塞配合索拉非尼治疗的临床效果观察
引用本文:翻军,孙咏涛. 43例肝细胞肝癌患者行肝动脉化疗栓塞配合索拉非尼治疗的临床效果观察[J]. 社区医学杂志, 2013, 11(2): 39-41
作者姓名:翻军  孙咏涛
作者单位:攀枝花市中心医院肿瘤科,四川,617067
摘    要:
目的探讨肝细胞肝癌患者在行肝动脉化疗栓塞配合索拉非尼治疗后的临床效果。方法选取2010年3月~2011年4月期间在攀枝花市中心医院住院治疗的73例中晚期肝细胞肝癌患者为研究对象。根据患者及其家属的意愿,将73例患者分为两组,观察组43例接受TACE联合索拉非尼治疗,对照组30例,采用单纯的TACE治疗。治疗3个月后比较两组患者的临床治疗效果以及患者治疗后半年、1年的生存率,并观察记录观察组患者的不良反应。结果观察组患者治疗3个月后治疗的总有效率明显优于对照组(P<0.05);观察组患者1年期的生存率显著高于对照组(P<0.05);观察组患者均有不同程度的不良反应,但经过相应处理后均能得到有效缓解和控制。结论经肝动脉化疗栓塞配合索拉非尼治疗肝细胞肝癌能有效控制疾病的快速发展,延长患者的生命,且无严重的毒副反应,临床上值得推广。

关 键 词:肝细胞肝癌  肝动脉化疗栓塞  索拉非尼

Transcatheter Arterial Chemoembolization with Sorafenib for Hepatocellular Carcinoma:Clinical Observation of 43 Cases
HU Jun,SUN Yong-tao. Transcatheter Arterial Chemoembolization with Sorafenib for Hepatocellular Carcinoma:Clinical Observation of 43 Cases[J]. journal of community medicine, 2013, 11(2): 39-41
Authors:HU Jun  SUN Yong-tao
Affiliation:Department of Oncology,Panzhihua Central Hospital,Sichuan,617067
Abstract:
Objective To study the clinical efficacy of transcatheter arterial chemoembelization (TACE) with sorafenlb in treating hepatocellular carcinoma. Methods Seventy - three hospitalized patients with middle to late stage of hepatccellular carcinoma were included from March 2010 to April 2011. According to the wishes of patients and their families, 73 patients were divided into two groups. Observation group ( n = 43) received TACE combined with ser- afenih, while control group ( n = 30) TACE alone. Both groups were compared for clinical efficacy after a 3 - month treat- ment and for 1 - year survival rate six months and one year after treatment. The adverse reactions in observation group were recorded and observed. Results After a 3 - month treatment, the total effective rate was significantly better in observation group than in control group (P 〈 0.05 ). The 1 -year survival rate was significantly higher in observation group than in control group (P 〈 0.05 ). Adverse reactions occurred in observation group to varying degrees, which could be effectively controlled after treatment. Condusions TACE with sorafenib can effectively control the rapid prngress of bepatoceUular carcinoma and prolong the lives of patients, with no serious toxicity and side effects, which is worthy of being applied clln- ically.
Keywords:hepatocellular carcinoma  TACE  sorafenib
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号